Sacubitril/valsartan reduces proteasome activation and cardiomyocyte area in an experimental mouse model of hypertrophy

Sacubitril/valsartan reduces proteasome activation and cardiomyocyte area in an experimental mouse model of hypertrophy

Sacubitril/valsartan (Sac/Val) belongs to the group of angiotensin receptor–neprilysin inhibitors and has been used for the treatment of heart failure (HF) for several years. The mechanisms that mediate the beneficial effects of Sac/Val are not yet fully understood. In this study we investigated whe...

Full description

Bibliographic Details
Main Authors: Moritz Meyer-Jens, Kristin Wenzel, Karina Grube, Julia Rüdebusch, Elisabeth Krämer, Martin Bahls, Kilian Müller, Hannah Voß, Hartmut Schlüter, Stephan B. Felix, Lucie Carrier, Stephanie Könemann, Saskia Schlossarek
Format: Article
Language:English
Published: Elsevier 2024-03-01
Series:Journal of Molecular and Cellular Cardiology Plus
Subjects:
Autophagy-lysosomal pathway
Cardiac function
Heart failure
Pressure overload
Sacubitril/valsartan
Ubiquitin-proteasome system
Online Access:http://www.sciencedirect.com/science/article/pii/S2772976123000296

Internet

http://www.sciencedirect.com/science/article/pii/S2772976123000296

Similar Items